We developed peripheral T cell cytotoxicity analysis as a biomarker of anti-PD-1 therapy based on our previous findings on the relationship between T cell cytotoxicity in the peripheral blood and tumor tissue of NSCLC patients18. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.